|
Japan’s pharmaceutical landscape is undergoing a transformative phase marked by rapid innovation and expansion, particularly in biopharmaceuticals. The ethical drug market in Japan has experienced remarkable growth, surpassing 11 trillion yen in 2023, marking a consecutive record high. Although the generics market has attained an 80 per cent volume share, its growth potential is limited. Conversely, the market for new drugs and patented products remains lucrative, ranking second globally after the United States.
Looking ahead, Japan is poised to witness sustained launches of new drugs in biopharmaceutical and specialty areas, attracting global attention. The Japanese government is actively promoting drug discovery efforts and addressing challenges related to ensuring a stable drug supply. Heightened focus on mid-molecular drugs like nucleic acids and peptides reflects evolving industry trends, while major pharmaceutical companies are exploring expansion into overseas markets to leverage Japan’s strong pharmaceutical capabilities. This dynamic landscape is further underscored by companies restructuring to enhance efficiency and focus on select research fields, alongside a growing trend of seeking new partners for outsourced manufacturing and API procurement.
The Japanese government is ramping up efforts to boost its pharmaceutical industry on a global scale. They’re all about innovation, pouring resources into research and development, and teaming up with international players to stay competitive. By smoothing out regulatory hurdles, they’re making it easier for drug approvals, giving local companies a better shot at success. Plus, they’re keen on building partnerships worldwide, knowing collaboration is key to staying ahead in the pharma game.
However, one significant challenge is ensuring a stable drug supply, which has become a major concern. Additionally, major pharmaceutical companies are contemplating expansion into overseas markets, highlighting the need to adapt to global demands. Furthermore, many companies are undergoing restructuring efforts to improve efficiency and select research fields strategically. Moreover, there’s a growing trend among companies to seek new partners for outsourced manufacturing and API procurement, reflecting a dynamic landscape in the Japanese pharmaceutical sector.
CPHI Japan event CPHI Japan 2024, widely seen as a barometer of overall health in the country’s pharma industry being held from April 17-19, 2024 at the Tokyo Big Sight, is expected to see more than 20 per cent year-on-year rise, with a record attendance as the country undergoes a post pandemic boom in pharma – with biologics and tides manufacturing expected to grow quickly.
The increased interest is attributed to a proactive regulatory framework and the country’s strong base of peptide and oligonucleotide chemistry and synthesis.
In the 21st edition of CPHI Japan, the heart of pharma, expects more than 20,000 attendees and approximately 680 suppliers from 28 countries and regions to introduce their latest products and technologies that support the supply chain in drug discovery, development, and manufacturing, from small molecules to biopharmaceuticals, said Jenny Leung, brand manager at CPHI Japan.
In addition, approximately 200 sessions will be held over during the exhibition, including presentations on the latest regulatory developments, trends, and cutting-edge technologies.
“To ensure the success of CPHI Japan 2024, we have implemented several new systems. For example, we’re collaborating with Tides to introduce a free conference in response to the growing interest in oligos and peptides manufacturing in Japan. The increased interest is attributed to a proactive regulatory framework and the country’s strong base of peptide and oligonucleotide chemistry and synthesis. Prof Hiroaki Suga of the University of Tokyo will present his predictions on the potential of mRNA and peptides at the event”, she added.
In addition, the event expects its highest ever number of visiting countries as interest in the Japanese pharma market remains high.
Collocated events The collocated events include the Tides conference, focusing on ‘Next Generation Special Cyclic Peptide Drug Discovery and Neobiologics Drug Discovery.’ This conference explores the country’s expanding role in the development of peptide drugs, which are among the most diverse architectures for current drug discovery efforts. Additionally, there’s the International Procurement Forum for APIs, hosted by the Japan Pharmaceutical Traders Association. This forum addresses issues related to the stable supply of APIs in Asia and Europe, with participants sharing their views from their respective positions and perspectives.
Major zones This year, the event will span five dedicated zones: Ingredients, Outsourcing, Biopharma, Machinery & Equipment, and DDS & Packaging. Each zone will showcase the latest advancements and offerings in its respective area. For example, the ingredients zone will highlight innovative ingredients used in pharmaceutical products, while the Biopharma zone will focus on biologics and their manufacturing processes.
Seminars and workshops At CPHI Japan 2024, attendees can expect an enriching lineup of seminars and workshops covering various aspects of the pharmaceutical industry. With over 200 industry-specific seminars held at the same venue as the exhibition space, participants will have ample opportunities to engage with speakers from diverse positions in the pharmaceutical industry.
To kick off the event, Kiyoto Nakai, Director of the Drug Evaluation and Control Division at the Pharmaceutical Affairs Bureau of the Ministry of Health, Labor, and Welfare, will deliver a keynote speech on “Latest Regulatory Trends” on April 17.
Additionally, on April 18, the Japan Pharmaceutical Manufacturers Association (JPMA) will present a keynote speech on “The Latest Trends in ICH Quality Guidelines” in collaboration with the Japan Pharmaceutical Manufacturers Association.
One of the highlighted events is the International Procurement Forum for APIs, hosted by the Japan Pharmaceutical Traders Association.
This annual forum, attended by more than 600 industry representatives, will address “Issues Concerning the Stable Supply of APIs,” sharing insights and perspectives from participants on the recent situation and challenges related to the stable supply of APIs in Asia and Europe.
The new addition TIDES Conference scheduled for April 18 at Ariake Central Tower Hall & Conference Hall, will explore “Next Generation Special Cyclic Peptide Drug Discovery and Neobiologics Drug Discovery” and will be presented by Professor Hiroaki Suga from the Graduate School of Science, The University of Tokyo.
Moreover, attendees can look forward to special guest lectures by industry experts. On April 17, Takashi Horii, Representative Director of AstraZeneca K.K., will deliver a special guest lecture entitled “AstraZeneca’s Pioneering Challenge.”
On April 19, Hironoshin Nomura, Executive Vice President and CFO of Sosei Group Corporation, will deliver a lecture entitled “Toward the Breakthrough of Biopharma from Japan.”
“We expect over 50 countries to be represented at the event this year. As for attendance numbers, we anticipate approximately 24000 unique visitors, marking a 20 per cent increase compared to 2023. Additionally, there will be over 680 exhibitors showcasing their offerings and capabilities in the pharmaceutical industry”, Jenny Leung added.
The major pavilions include the China Pavilion, Korea Pavilion, Italy Pavilion, Japan Pavilion by Japan Bulk Pharmaceutical Manufacturing Association (JBPMA), and the Japan Pharmaceutical Excipients Council Pavilion. These pavilions will showcase the offerings and capabilities of their respective countries in the pharmaceutical industry.
Prospects of Indo-Japanese pharma trade The prospects of Indo-Japanese pharma trade look promising. Both countries have strong pharmaceutical industries, and there’s a lot of potential for collaboration. India’s expertise in cost-effective generic drugs complements Japan’s innovative research and development capabilities. With growing healthcare needs in both countries and supportive government policies, there are great opportunities for mutual growth. By working together, we can share knowledge and resources, driving innovation and addressing healthcare challenges. Overall, the Indo-Japanese pharma trade holds a lot of promise for strategic partnerships and advancements in the global pharmaceutical market, Leung stated.
|